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ttp://dx.doi.org/10.1016/j.ajpath.2014.04.011Thyroid carcinoma is the most common endocrine malignancy, and papillary thyroid carcinoma repre-
sents the most common thyroid cancer. Papillary thyroid carcinomas that invade locally or metastasize
are associated with a poor prognosis. We found that, during epithelialemesenchymal transition (EMT)
induced by transforming growth factor-b1 (TGF-b1), papillary thyroid carcinoma cells acquired
increased cancer stem cell-like features and the transcription factor paired-related homeobox protein 1
(PRRX1; alias PRX-1), a newly identiﬁed EMT inducer, was markedly up-regulated. miR-146b-5p was also
transiently up-regulated during EMT, and in siRNA experiments miR-146b-5p had an inhibitory role on
cell proliferation and invasion during TGF-b1einduced EMT. We conclude that papillary thyroid carci-
noma tumor cells exhibit increased cancer stem cell-like features during TGF-b1einduced EMT, that
miR-146b-5p has a role in cell proliferation and invasion, and that PRRX1 plays an important role in
papillary thyroid carcinoma EMT and disease progression. (Am J Pathol 2014, 184: 2342e2354; http://
dx.doi.org/10.1016/j.ajpath.2014.04.011)Supported by NIH grant R01-CA121115 (H.C.) and American Cancer
Society MEN2 Thyroid Cancer Professorship (H.C.), by start-up funding
from the Department of Pathology (R.V.L.), and by NIH Cancer Center
Support Grant P30-CA014520-39 to the University of Wisconsin Carbone
Cancer Center.
Disclosures: None declared.Thyroid carcinoma is the most common endocrine malig-
nancy, and the most frequent type of thyroid cancer is
papillary thyroid carcinoma (PTC), which makes up
approximately 80% of thyroid cancers worldwide.1 Most
patients with PTC have an excellent prognosis, but a small
number of patients with aggressive PTC develop invasive
tumors and/or distant metastases.1e3 To treat these patients
more effectively, greater understanding of the mechanisms
regulating tumor progression in aggressive PTC is needed.
Epithelialemesenchymal transition (EMT) has been stud-
ied extensively during embryogenesis4 and in cancer pro-
gression.5e10 EMT inducers include cytokines, such as
transforming growth factor beta-1 (TGF-b1),11,12 and tran-
scription factors. TGF-b1 is a multifunctional cytokine that
acts as a tumor suppressor in early tumor development and
promotes tumor cell growth in later stages.13 Transcription
factors linked to EMT include Snail, Slug, Twist, Zeb1, and
Zeb2.14 Recent studies have linked EMTwith cancer stem-like
cells (CSCs) in mammary carcinomas.8,9 Some of the genes
regulating EMT in thyroid cancer have been analyzed in recentstigative Pathology.
.years,10,15e17 but new inducers of EMT such as paired-related
homeobox protein 1 (PRRX1; alias PRX-1) have also been
reported.18,19 PRRX1 expression has been reported to play an
important role as a key switch for neural cell lineage deter-
mination and in the maintenance of self-renewal of adult
neural stem cells in the normal adult brain.18 Furthermore, in
the anterior pituitary of rats, PRRX1 is produced in pituitary
progenitor cells and may have a role in terminal differentiation
during early pituitary organogenesis.19 PRRX1 has recently
been observed to promote EMT in breast,20 pancreas,21 and
colon22 cancers. In some tumors such as breast cancer, how-
ever, low PRRX1 levels were associated with metastasis and
poor prognosis in clinical samples,20 whereas in colorectal
adenocarcinomas abundant PRRX1 expression was associated
PRRX1 and miR-146b-5p in Thyroid Cancerwith metastasis and poor prognosis.22 The role of PRRX1 in
tumor progression of thyroid cancer is unknown.
miRNAs are a class of small noncoding RNAs of 18 to 25
nucleotides that are involved in post-transcriptional gene
regulation by pairing with 30 untranslated regions of target
mRNAs.23 Studies have shown the importance of speciﬁc
miRNAs in thyroid cancer development and progression.24e27
Several studies, especially in breast carcinomas, have shown a
regulatory role of miR-146 on various proteins inﬂuencing
tumor invasion and metastasis.28e31 Breast cancer metastasis-
suppressor 1 (BRMS1) has been shown to inﬂuence miR-146
expression. Nuclear factor-kB (NF-kB), which is regulated by
BRMS1 and miR-146, plays an important role in thyroid
cancer progression, by controlling the proliferative and anti-
apoptotic signaling pathways of thyroid carcinomas.32 NF-kB
is associated with regulation of anaplastic thyroid carcinoma
(ATC) via up-regulation of miR-146a expression.33 Over-
expression of miR-146b has been shown to reduce glioma
growth in primary brain tumors.34,35 Some studies have shown
that TGF-b1 regulates speciﬁc miRNAs such as miR-146b-5p
in normal cells and in cancers such as PTC.24,27 Because TGF-
b1 also regulates EMT in PTC,17 this growth factor may have
important roles in both EMT and speciﬁc miRNA expression
in thyroid cancer progression.
Our aim was to analyze the inﬂuence of TGF-b1 on
PRRX1 and miR-146b-5p during EMT in PTC and to
determine their inﬂuence on thyroid cancer progression.
Here, we show that TGF-b1 up-regulates PRRX1 expres-
sion in PTC cell lines and that miR-146b-5p has a regulatory
role on PTC proliferation and invasiveness during EMT.
Materials and Methods
Cell Culture and TGF Treatment
The papillary thyroid carcinoma cell line BCPAP was pro-
vided by Dr. Rebecca E. Schweppe (University of Colorado,
Denver, CO) and the TPC-1 cell line was provided by Dr.
Daniel T. Ruan (Brigham and Women’s Hospital, Boston,
MA). Both cell lines were maintained in RPMI 1640 medium
with 10% fetal bovine serum and 1% penicillinestreptomycin
at 37C in a 5% CO2eenriched atmosphere. The ATC cell
lines THJ-16T and THJ-21T36 were kindly provided by Dr.
John A. Copland III (Mayo Clinic, Jacksonville, FL) and were
maintained in RPMI 1640 medium with 10% fetal bovine
serum, 1% nonessential amino acids, 1% sodium pyruvate,
and 1% penicillinestreptomycin at 37C, 5% CO2.
To induce EMT, the cell lines were plated at a density of
1  105 per 75-mm ﬂask, cultured with serum-free medium
(modiﬁed from Fierabracci et al,37 with EGF and FGF omitted)
with (treated) or without (control) 2 ng/mL human recombinant
TGF-b1 (R&D Systems, Minneapolis, MN) for 30 days. Me-
dium was replaced every 2 to 3 days. Control and treated cells
were trypsinized, counted, and reinoculated at the original
density every 7 days for 30 days; the remaining cells were
collected for additional assays and analysis. Originally, theThe American Journal of Pathology - ajp.amjpathol.orgexperimental design used a 10-day interval for analysis; how-
ever, for both cell lines the proliferation rate of the control
exceeded the 10-day period, and the design was subsequently
altered to a 7-day interval. To verify the authenticity of the TPC-
1 andBCPAP cell lines, DNA short tandem repeat STR analysis
was performed by DDC (DNA Diagnostics Center, Fairﬁeld,
OH). Both cell lines were tested using 19 markers and were
found to be authentic.
Sphere Formation
TGF-b1etreated and control TPC-1 cells were collected at
day 1 and day 14 of culture treatment, and 1  103 cells
were plated into a six-well Ultra-Low attachment plate
(Corning Life Sciences, Tewksbury, MA) with spheroid
medium [modiﬁed from Fierabracci et al,37 with 1 B27
supplement added (Gibco; Life Technologies, Carlsbad,
CA)] and were cultured for 5 days to allow sphere forma-
tion. Spheres were measured and counted to assess sphere-
forming capacity. Only spheres 50 mm were counted.
Flow Cytometry
TGF-b1etreated and control TPC-1 and BCPAP cells were
harvested and stained with a Molecular Probes dead cell
apoptosis kit (Life Technologies) with annexin V, Alexa
Fluor 488, and propidium iodide on days 7, 14, and 21 to
analyze apoptosis. Tumor xenografts were harvested and
enzymatically digested, and aldehyde dehydrogenase ac-
tivity was analyzed with an ALDEFLUOR kit (STEMCELL
Technologies, Vancouver, BC, Canada) according to the
manufacturer’s instructions. All ﬂow cytometry was per-
formed on a BD FACSCalibur platform (BD Biosciences,
San Jose, CA), and data were analyzed with Cyﬂogic soft-
ware version 1.2.1 (CyFlo, Turku, Finland).
RNA Isolation and RT-qPCR
Total RNA was extracted from samples with TRIzol reagent
(Life Technologies) according to the manufacturer’s in-
structions, and RNA quality and concentrations were
assessed with a NanoDrop 1000 spectrophotometer (Thermo
Fisher Scientiﬁc, Waltham, MA). To assess mRNA expres-
sion, total RNA of 1 mg was reverse-transcribed using an All-
in-One ﬁrst-strand cDNA synthesis kit (GeneCopoeia,
Rockville, MD). RT-qPCR was performed on a CFX96 PCR
detection system (Bio-Rad Laboratories, Hercules, CA)
using Bullseye EvaGreen qPCR master mix (MIDSCI, St.
Louis, MO), normalized to 18S rRNA; relative fold change
was determined by the DD CT method. The PCR primers
used are listed in Table 1 except E-cadherin, which was
purchased from SABiosciences (Qiagen, Valencia, CA).
To assess miRNA expression, 1 mg of total RNA was
reverse-transcribed using an All-in-One miRNA RT-qPCR
detection kit (GeneCopoeia). RT-qPCR was performed on a
CFX96 PCR detection system (Bio-Rad Laboratories),2343
Table 1 Primers Used for RT-qPCR Assays
Primer Forward Reverse
18S 50-GTAACCCGTTGAACCCCATT-30 50-CCATCCAATCGGTAGTAGCG-30
SOX2 50-GCACATGAACGGCTGGAGCAACG-30 50-TGCTGCGAGTAGGACATGCTGTAGG-30
OCT4 50-AGCCCTCATTTCACCAGGCC-30 50-CAAAACCCGGAGGAGTCCCA-30
Slug 50-ATGCATATTCGGACCCACAC-30 50-GCAGATGAGCCCTCAGATTT-30
Snail 50-CCCAATCGGAAGCCTAACTA-30 50-CAGGACAGAGTCCCAGATGAG-30
Vimentin 50-TCCAGCAGCTTCCTGTAGGT-30 50-CCCTCACCTGTGAAGTGGAT-30
Twist 50-CATCGACTTCCTCTACCAGGTC-30 50-TCCATTTTCTCCTTCTCTGGAA-30
Zeb1 50-GCACAACCAAGTGCAGAAGA-30 50-GCCTGGTTCAGGAGAAGATG-30
Zeb2 50-CAAGAGGCGCAAACAAGC-30 50-GGTTGGCAATACCGTCATCC-30
PRRX1 50-CTGATGCTTTTGTGCGAGAA-30 50-ACTTGGCTCTTCGGTTCTGA-30
cMET 50-GATTTTAGTCATCCCAATGTCC-30 50-ATCCAGCATACAGTTTCTTGC-30
EGFR 50-ATGTCCGGGAACACAAAGAC-30 50-TTCCGTCATATGGCTTGGAT-30
Hardin et alnormalized to RN5; relative fold change was determined by
the DD CT method. All primers used for miRNA detection
were purchased from GeneCopoeia.
Western Blot Analysis
Treated and control TPC-1 and BCPAP cells at three time
points (days 7, 14, and 21) were washed twice with phosphate-
buffered saline (PBS), and then radioimmunoprecipitation
assay lysis buffer was added. The protein lysates were pre-
pared as described previously.38 In brief, protein concentration
was quantiﬁed using a Pierce BCA protein assay kit (Thermo
Fisher Scientiﬁc) according to the manufacturer’s instructions.
Equal amounts of denatured protein were resolved by elec-
trophoresis on 4% to 15% Criterion TGX precast gels (Bio-
Rad Laboratories), transferred onto nitrocellulose membranes
(Bio-Rad Laboratories), blocked in 5% nonfat milk solution,
then incubated overnight at 4C with the following primary
antibodies: Twist (dilution 1:500; Abcam, Cambridge, MA);
Snail (dilution 1:1000; Novus Biologicals, Littleton, CO);
Slug (dilution 1:1000), E-cadherin (dilution 1:1000), and
b-actin (dilution 1:2000) (Cell Signaling Technology, Dan-
vers, MA); or PRRX1 (dilution 1:1000; Sigma-Aldrich, St.
Louis, MO). Membranes were washed the next day and then
incubated for 1 hour at room temperature with horseradish
peroxidaseeconjugated secondary antibodies (dilution
1:2000; Cell Signaling Technology). The immunoreactive
protein bands were visualized by Immun-Star (Bio-Rad Lab-
oratories) or by Pierce SuperSignal West Pico or SuperSignal
West Femto (Thermo Fisher Scientiﬁc) chemiluminescent
detection systems. b-Actin was used as the loading control.
siRNA Transfection, Proliferation, and Invasion Assays
Control and TGF-b1etreated cells were seeded into a 96-well
plate at 1  104 cells per well (10 replicates each) in 100 mL
serum-free/antibiotic-free medium with or without 2 ng/mL
TGF-b1. Wells were transfected with 10 nmol/L of miR-
CURY LNA miRNA power inhibitor to hsa-mir-146b-5p
(sequence: 50-GCCTATGGAATTCAGTTCTC-30) or miR-
CURY LNA microRNA Inhibitor Negative Control A2344(sequence: 50-GTGTAACACGTCTATACGCCCA-30) (Exi-
qon, Woburn, MA; Vedbaek, Denmark) or MISSION syn-
thetic miRNA inhibitor to hsa-mir-146b-5p (sequence:
50-UGAGAACUGAAUUCCAUAGGCU-30) (Sigma-Aldrich)
using X-tremeGENE siRNA transfection reagent (Roche Di-
agnostics, Indianapolis, IN) for 72 hours at 37C in a 5%
CO2eenriched atmosphere. After 72 hours of incubation, cell
proliferation and invasion were assayed using a Vybrant MTT
cell proliferation assay kit (Life Technologies) and a Cultrex
BME cell invasion assay (R&D Systems) according to the
manufacturer’s protocol. The 96-well plate for the invasion
assay was coated with 0.1 BME basement membrane extract
overnight before seeding cells. Read-out for the MTT assay
was performed using a SpectraMax 190 absorbance micro-
plate reader (Molecular Devices, Sunnyvale, CA); a Synergy 2
multimode microplate reader (BioTek Instruments, Winooski,
VT) was used to analyze the cell invasion assay.
Tumor Xenografts
TGF-b1etreated and control cells were cultured for 30 days
as described above. The cells were harvested and 1  105
cells were injected subcutaneously into 30 nude mice
10 mice per treatment group (Jackson Laboratory, Bar
Harbor, ME) in 1:1 serum-free medium/growth factore
reduced Matrigel (BD Biosciences), with three injection
sites per mouse for TPC-1 and BCPAP cells. Tumors were
measured with calipers once a week, and they were har-
vested after 10 weeks and processed for further analysis.
Immunoﬂuorescence Studies
In situ immunoﬂuorescence staining for vimentin and
cytokeratin 19 was performed on day 8 on TGF-b1etreated
and control TPC-1 cells in a six-well plate. The cells were
ﬁxed with methanol for 5 minutes and washed three times
with PBS. The cells were blocked with 2.5% horse serum,
and primary antibody to vimentin (dilution 1:200) and
cytokeratin 19 (dilution 1:20) was added overnight at 4C.
Alexa Fluor 488 goat anti-rabbit IgG (dilution 1:500; Life
Technologies) was added for 30 minutes; after a wash withajp.amjpathol.org - The American Journal of Pathology
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Technologies) was added to the well to stain nuclei. Images
were captured with an Eclipse TI ﬂuorescence microscope
(Nikon, Tokyo, Japan) and analyzed with NIS Elements
software version 3.01 (Nikon).
Immunoﬂuorescence staining was performed to detect E-
cadherin in control and TGF-b1etreated cell lines. The TPC-
1 cell line was prepared on cytospin slides after 14 days of
treatment. Slides were ﬁxed with 4% paraformaldehyde for 5
minutes and washed three times with PBS. Epitope retrieval
was performed using 10 mmol/L of citrate buffer (pH 6) in a
microwave oven for 5 minutes. The cells were then incubated
with 2.5% horse serum for 1 hour before antieE-cadherin
rabbit monoclonal antibody (dilution 1:400; clone 24E10;
Cell Signaling Technology) was added overnight at 4C.
Alexa Fluor 555 goat anti-rabbit IgG (dilution 1:500; Life
Technologies) was added for 30 minutes, followed by a wash
with PBS and mounting with ProLong Gold antifade reagent
with DAPI (Life Technologies).
TMA
Three tissue microarrays (TMAs) were constructed as
described previously19 from 193 case samples of formalin-
ﬁxed, parafﬁn-embedded tissues: 10 normal thyroid (NT),
10 nodular goiter (NG), 32 follicular adenoma (FA), 28
follicular carcinoma (FC), 57 PTC, 21 poorly differentiated
carcinoma (PDC), and 35 ATC. The ﬁrst TMA comprised 147
cases, including only 10 of the ATCs and omitting all PD
carcinomas; the second TMA comprised the 21 PD carci-
nomas, and the third TMA comprised 25 ATCs. The TMAThe American Journal of Pathology - ajp.amjpathol.orgconsisted of triplicate 0.6-mm cores made using a manual
TMA (Beecher Instruments, Sun Prairie, WI). The NT con-
sisted of tissues from the opposite (histologically normal)
thyroid lobe in patients with follicular or papillary carcinomas.
The study was approved by the Institutional Review
Board at the University of WisconsineMadison.
TMA and Whole Tissue Section IHC
Automated immunostaining of the TMAs for PRRX1 was
performed as described previously.15 All immunolabeling was
performed at room temperature using a Lab Vision 360 LV-1
Autostainer system (Thermo Fisher Scientiﬁc). Except as
noted, reagents were from Biocare Medical (Concord, CA).
PRRX1 rabbit polyclonal antibody (NBP2-13816; Novus
Biologicals) was diluted 1:20 and incubated for 60 minutes,
followed by incubation with biotinylated goat anti-rabbit IgG
for 15 minutes and then 4þ streptavidinehorseradish perox-
idase treatment for 15 minutes. Betazoid diaminobenzidene
and Mayer’s hematoxylin were each incubated for 1 minute.
Primary antibodies were omitted in negative controls, which
resulted in no staining. For positive controls, ATCs previously
shown to express the antigen of interest by immunohisto-
chemistry (IHC) and by RT-qPCR were used.
PRRX1 staining on TMAs was evaluated based on the
presence or absence of nuclear immunoreactivity in thyroid
epithelial cells. Staining patterns were examined by three
independent reviewers (R.V.L., C.M.G., and Z.G.). Nuclear
staining for PRRX1 was interpreted based on intensity,
which was scored as negative (0), weak (1þ), moderate
(2þ), and strong (3þ). Expression was considered focal ifFigure 1 TGF-b1 treatment up-regulates EMT
marker expression in TPC-1 cells. A: In situ staining
of attached cultures with cytokeratin 19 antibody
on day 8 revealed decreased expression in spindle
cells of TGF-b1etreated TPC-1 cells, as well as
increased expression of the classic EMT marker
vimentin. TGF-b1etreated and untreated TPC-1
cells were stained for the adhesion marker E-cad-
herin on day 14 cytospin-prepared slides; protein
expression decreased in TGF-b1etreated cells. B:
RT-qPCR results from treated and untreated TPC-1
cells at days 8, 20, and 30 indicated signiﬁcant
loss of E-cadherin expression and signiﬁcant in-
crease in the EMT markers Slug, Snail, Twist, and
vimentin in TGF-b1etreated cells. C: Western blot
analysis of the EMT markers Slug and Snail on TGF-
b1etreated and untreated TPC-1 cells assessed on
days 7, 14, and 21 of culture. Analysis shows
increased slug and twist production in TGF-b1
treated cells consistent with RT-qPCR results.
b-Actin was used as a control. Data are expressed as
means  SEM for ﬁve experiments. *P < 0.05;
**P < 0.01. Scale barZ 50 mm. Original magniﬁ-
cation: 100 (A); 200 (B). ECAD, E-cadherin;
TGFb, TGF-b1.
2345
Figure 2 In vitro TGF-b1 treatment inhibits growth of TPC-1 cells. A:
TPC-1 cells were cultured in serum-free medium with (black bars) or without
(gray bars) 2 ng/mL TGF-b1 for 21 days, with the culture medium renewed
every 2 to 3 days. TGF-b1 exhibited in vitro growth inhibition on TPC-1
cells. B: Annexin V staining and ﬂow cytometry indicated that growth in-
hibition was due in part to apoptosis. Data are expressed as means  SEM
for two experiments *P < 0.05.
Hardin et alpositive cells comprised 2% to 25% of all tumor cells in the
TMA sample and diffuse if this proportion was greater than
25%. Focal staining of less than 1% of all tumor cells was
considered to be negative.
Whole sections of formalin-ﬁxed, parafﬁn-embedded
lymph node tissues corresponding to seven PTCs and one
ATC represented on the TMAs were also used for immu-
nostaining for PRRX1. In addition, whole sections of
formalin-ﬁxed, parafﬁn-embedded tissue sections of ﬁve
conventional PTCs, ﬁve tall-cell PTCs, and ﬁve PTCs with
hobnail features were used for PRRX1 immunostaining.
Statistical Analysis
Continuous variables were assessed by Student’s t-test.
Categorical variables were compared with the c2 test.
Multivariate prognostic analyses were performed with a Cox
proportional hazards regression model. All statistical ana-
lyses were performed using IBM SPSS Statistics software
version 21.0 (IBM, Armonk, NY) and GraphPad Prism
software version 6.0 (GraphPad Software, La Jolla, CA).
Two-tailed P values of <0.05 were considered to be sta-
tistically signiﬁcant. Data are expressed as means  SEM.
Results
TGF-b1 Treatment Induces EMT in PTC Cells
To investigate the role of TGF-b1 on the development of
EMT in PTC cells, we used long-term in vitro culture with
subsequent inoculation into nude mice. PTC cell lines TPC-
1 and BCPAP were cultured in a modiﬁed serum-free me-
dium for a period of 30 days and were analyzed at regular
intervals to assess EMT marker expression. TGF-b1 treat-
ment induced EMT in PTC cells, as evident from the pro-
duction of spindle cells, down-regulation of E-cadherin and
cytokeratin 19, and up-regulation of vimentin, Slug, Snail,
and Twist in both TPC-1 cells (Figure 1) and BCPAP cells
(Supplemental Figure S1). A signiﬁcant decrease in the
expression of E-cadherin was seen early in TGF-b1 treat-
ment of both PTC cell lines; however, TPC-1 control cells
also down-regulated E-cadherin, because of the serum-free
environment of the culture medium (Figure 1B), whereas
BCPAP control cells maintained signiﬁcant E-cadherin
expression (Supplemental Figure S1). The transcription
factors Slug and Snail were signiﬁcantly up-regulated in
both cell lines at all time points analyzed, whereas Twist
was expressed variably in both cell lines. Vimentin was
increased by TGF-b1 treatment, but the increase was sig-
niﬁcant only in the TPC-1 cell line (Figure 1, B and C).
The effects of TGF-b1 on proliferation of TPC-1 and
BCPAP cancer cell lines are not well known. Analysis of the
proliferation rate of two cell lines of TGF-b1etreated and
control cells revealed a reduction in growth in TPC-1 cells
(Figure 2A) and early inhibition of BCPAP cell proliferation
(data not shown) but with recovery by day 21. Flow2346cytometric analysis of annexin V staining revealed that this
inhibition was due in part to TGF-b1einduced apoptosis in
both TPC-1 cells (Figure 2B) and BCPAP cells (data not
shown). RT-qPCR and IHC analyses showed that both cell
lines had equal expression of TGF-b receptor type-1 (TGF-
bR1), SMAD2, and SMAD4 (data not shown). Taking into
account that the cell lines expressed pathway components,
the exerted growth inhibition and induced apoptosis under
TGF-b1 treatment indicate that the TGF-b1 pathway is intact
and functional in both TPC-1 and BCPAP cells.
TGF-b1 Treatment Induces Tumorigenicity in PTC Cells
After the initial in vitro culture period of 30 days, 10% serum,
serum-free, and TGF-b1etreated cells were injected subcu-
taneously into 30 nude mice (n Z 10 mice per treatment
group, with three injection sites per mouse) to assess tumor
formation and growth (Figure 3A). TGF-b1etreated TPC-1
cells formed tumors at a signiﬁcantly accelerated rateajp.amjpathol.org - The American Journal of Pathology
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weeks, compared with control and cells grown in 10% serum
(Figure 3C). TGF-b1 treatment also tended to increase tumor
size of BCPAP cells, compared with control cells, but the
difference was not signiﬁcant because of marked variation in
tumor size (Supplemental Figure S2). BCPAP cells cultured
in 10% serummedium did not grow tumors. Tumors from the
xenografts were analyzed for morphological features and for
EMT marker expression (Figure 4). The morphology of
serum-free treated TPC-1 and BCPAP tumors included thy-
roid carcinomas with epithelioid cells, whereas the TGF-
b1etreated TPC-1 tumors exhibited a more spindle-cell
morphology, with skeletal muscle invasion in some tumors
(Figure 4A). Interestingly, the BCPAP tumors treated with
TGF-b1 also exhibited an epithelioid morphology, but with
vascular invasion in a few cases (Figure 4A). Tumors were
also analyzed for EMT markers by RT-qPCR (Figure 4B)
and Western blotting and densitometry (Figure 4C). Tumor
EMT marker expression remained constant and correlated
well with the in vitro analysis.
Because the signiﬁcant growth of TGF-b1etreated TPC-
1 cells was probably not explained solely by EMT induc-
tion, we analyzed stem cell markers. In vitro cultures ofFigure 3 TGF-b1 treatment on TPC-1 cells induces tumor formation in vivo. A:
TPC-1 cells cultured for 30 days in medium containing 10% fetal bovine serum, seru
inoculations per treatment: 3 injection sites per mouse, and 10 mice per treatmen
calipers (height  length  width). After 10 weeks, mice were euthanized and
Representative tumors are shown (arrows). B: Growth curves for TPC-1 tumors sho
control or 10% serumetreated tumor. C: TGF-b1etreated TPC-1 cells produced m
with either 10% fetal bovine serum (15/30, 50%) or serum-free medium (17/30, 57
per treatment group. *P < 0.05.
The American Journal of Pathology - ajp.amjpathol.orgTPC-1 treated and control cells, as well as cells grown in
10% serum, were analyzed by RT-qPCR for the stem cell
markers OCT4 and SOX2 (Figure 5A). The PCR results
indicated a signiﬁcant up-regulation of OCT4 by TGF-b1
treatment; however, control cells also up-regulated OCT4,
because of serum-free culture stresses. Furthermore, TGF-
b1 signiﬁcantly up-regulated SOX2 very early in treatment,
but the control cells also reached that threshold level by day
30. PCR results for the 10% serum condition showed very
low levels of both transcription factors (data not shown).
Because in vitro markers did not fully elucidate the dif-
ferences in tumor cell proliferation between the treated and
control cells, we hypothesized that our experimental design
selected for CSCs (ie, tumor-initiating cells). TGF-
b1etreated and control cells from 24-hour to 14- day in vitro
cultures were placed in ultra-low attachment plates with
sphere formation medium for 5 days, to analyze self-renewal
properties. There was no difference in the 24-hour culture
assay between the treated and control cells; however, 14-day
TGF-b1etreated cells produced a signiﬁcantly greater
number of spheres, compared with control cells (Figure 5, B
and D), suggesting a greater self-renewal potential. Addi-
tionally, ﬂow cytometric ALDEFLUOR analysis revealedSix-weekeold female nude mice were injected subcutaneously with 1  105
m-free medium, or serum-free medium with 2 ng/mL TGF-b1. There were 30
t group. Mice were monitored weekly, and tumor growth was assessed with
the tumors were harvested, weighed, and processed for further analysis.
w that TGF-b1etreated tumors grew signiﬁcantly faster than the serum-free
ore tumors and signiﬁcantly larger tumors (20/30, 67%) than cells treated
%). Data are expressed as means  SEM for three experiments. nZ 10 mice
2347
Figure 4 TGF-b1 treatment induces EMT and aggressiveness in xenografts. A: To assess morphology, TPC-1 and BCPAP control and TGF-b1etreated tumors
were stained with hematoxylin and eosin. In both cell lines, the control tumors were thyroid carcinoma with an epithelioid morphology. The TPC-1 TGF-
b1etreated tumors were thyroid carcinoma with spindle-shaped cells, sometimes with skeletal muscle invasion (SM). The BCPAP TGF-b1etreated tumors were
thyroid carcinoma with an epithelioid morphology, sometimes with evidence of vascular invasion (arrow). B: TGF-b1 (gray bars) and control (black bars)
mediumetreated PTC tumors were analyzed for the EMT markers E-cadherin, Slug, Snail, and Twist. RT-qPCR indicated signiﬁcant down-regulation of E-
cadherin and signiﬁcant up-regulation of Slug and Snail in both TPC-1 (left) and BCPAP (right) TGF-b1etreated tumors. C: Analysis of EMT marker protein
expression in PTC tumors by Western blotting and densitometry analysis revealed an increase in EMT proteins Slug and Twist and a decrease in E-cadherin in
TGF-b1etreated tumors. Data are expressed as means  SEM for two experiments. *P < 0.05, **P < 0.01, and ***P < 0.001. Scale bar Z 75 mm. Original
magniﬁcation, 200.
Hardin et althat TGF-b1etreated tumor cells had a signiﬁcantly greater
amount of aldehyde dehydrogenase activity than either the
control or 10% serumetreated tumor cells (Figure 5C),
indicating a greater number of CSCs within the tumor pop-
ulation of TGF-b1etreated tumors.
TGF-b1 Induces PRRX1 Expression
Recently, the novel homeobox transcription factor PRRX1 has
been reported to be an EMT inducer and involved in tumori-
genicity and metastasis20e22; however, the role of PRRX1 in
thyroid carcinoma is unknown. To investigate whether
PRRX1 plays a role in TGF-b1einduced EMT of PTC, TGF-
b1etreated and control TPC-1 cells were tested for PRRX1
expression by RT-qPCR, Western blotting, and immunoﬂuo-
rescence (Figure 6). PRRX1 was signiﬁcantly up-regulated in
TGF-b1etreated cells (Figure 6A) from as early as day 7, and
this effect remained signiﬁcant through day 30. Control and
TGF-b1etreated TPC-1 and BCPAP xenograft tumors were2348also tested for PRRX1 expression, and TGF-b1etreated tu-
mors exhibited signiﬁcant up-regulation of PRRX1, compared
with the control mediumetreated tumors (Figure 6, D and E).
In two ATC cell lines tested for PRRX1 expression (THJ-16T
and THJ-21T), the 21T cells had very high levels of PRRX1,
whereas levels in 16T cells were similar those of TPC-1 cells
(data not shown).
Prognostic Implication of PRRX1 Expression in Thyroid
Tissues
IHC analysis of the TMA is summarized in Table 2. IHC
staining with PRRX1 antibody revealed nuclear localization
of PRRX1 protein (Figure 7). The intensity of PRRX1
expression was moderate to strong. The ATC group had the
highest percentage of cases staining for PRRX1, with nu-
clear expression in 20/35 (57.7%) ATCs in the TMAs,
compared with all other groups, whereas PTCs, PDCs, and
NGs were all negative for staining. PRRX1 staining wasajp.amjpathol.org - The American Journal of Pathology
Figure 5 TGF-b1 up-regulates stem cell markers in TPC-1 cells. A: TPC-1
cells cultured for 30 days with (black bars) or without (gray bars) TGF-b1
were analyzed on days 7, 14, 21, and 30 for the stem cell markers OCT4 and
SOX2. RT-qPCR analysis indicated up-regulation of the stem cell markers
OCT4 and SOX2 after TGF-b1 treatment. B: Day 1 and day 14 TGF-
b1etreated and untreated cells were incubated in ultra-low attachment six-
well plates in spheroid medium for 5 days to assess thyrosphere formation.
Spheres with diameter of 50 mm were counted. Day 14 TGF-b1etreated
cells formed many more thyrospheres than did the untreated cells, indi-
cating an increase in stem-like cells with self-renewal properties under TGF-
b1 treatment. C: Xenograft tumors from 30-day cultured TPC-1 cells
(Figure 2A) were harvested after 10 weeks without TGF-b1etreatment and
analyzed for ALDEFLUOR activity by ﬂow cytometry. TGF-b1einduced tu-
mors exhibited a twofold increase in ALDEFLUOR activity, compared with
controls, indicating a signiﬁcant increase in stem-like cell populations
within the tumors. D: Representative images of day 14 thyrospheres of TGF-
b1etreated and control TPC-1 cells. Data are expressed as means  SEM for
two experiments. *P < 0.05; **P < 0.01. Scale bar Z 250 mm.
PRRX1 and miR-146b-5p in Thyroid Cancerpositive in 1/32 (3%) FAs, 1/28 (4%) FCs, and 2/10 (20%)
NTs (Table 2). PRRX1 was also expressed in inﬂammatory
cells, ﬁbroblasts, and endothelial cells.
The whole sections of lymph node tissues with metastatic
carcinomas were analyzed for PRRX1 expression. The
seven PTCs corresponding to cases on the TMA were all
negative for PRRX1, but the one ATC case was positive in
both the lymph node metastasis and in the primary tumor
(data not shown). In another set of experiments, analysis of
whole tissue sections of ﬁve conventional PTCs and ﬁve
tall-cell variant PTCs were all negative for PRXX1; how-
ever, 2/5 (40%) PTCs with hobnail features were positive
for PRRX1 (Figure 7).The American Journal of Pathology - ajp.amjpathol.orgmiR-146b-5p Is Induced by TGF-b1 and Is Inhibitory
to PTC Proliferation and Invasion
Several research groups have performed miRNA proﬁling of
thyroid carcinomas and report that miR-146b-5p is one of
the most up-regulated miRNA in PTC.24e26 Nonetheless,
not many functional studies have been performed with this
miRNA in thyroid carcinoma. We tested PTC cell lines by
RT-qPCR for miR-146b-5p expression and found that miR-
146b-5p was expressed at low levels in PTC-1 and BCPAP
cells (data not shown). Interestingly, RT-qPCR showed a
signiﬁcant up-regulation of miR-146b-5p with TGF-b1
treatment in both cell lines; however, this up-regulation was
transient (Figure 8A). BCPAP results were similar (data not
shown). PCR analysis showed a signiﬁcant up-regulation of
miR-146b-5p by approximately days 10 to 14, with reduced
expression by day 21 in ﬁve independent experiments.
Given these ﬁndings, we conducted further investigations.
A miRNA silencing inhibitor (siRNA) comprising a pool
of ﬁve separate sequences to miR-146b-5p was transfected
into TGF-b1etreated and control cells on day 14, and
proliferation and invasion studies were performed. RT-
qPCR conﬁrmed inhibition of miR-146b-5p by the chosen
siRNA (Supplemental Figure S3). MTT assays indicated
that the proliferation rate of both TGF-b1etreated and
control TPC-1 cells was signiﬁcantly increased by miR-
146b-5p knockdown (Figure 8B). BCPAP cells exhibited
similar changes, but the differences did not reach signiﬁ-
cance (data not shown). Invasion assays using a basement
membrane extract were used to analyze invasive potential
of TGF-b1etreated and control cells. Intriguingly, miR-
146b-5p inhibition did not alter the invasive properties of
TGF-b1etreated cells, but signiﬁcantly increased the inva-
siveness of control cells to a level equal to or greater than
that of TGF-b1etreated cells (Figure 8C). A second siRNA
with a different pool of sequences to miR-146b-5p was then
used, and this conﬁrmed the results of the original siRNA
(Supplemental Figure S4).Discussion
The EMT program in which cancer cells acquire a mesen-
chymal phenotype has been proposed as a critical mecha-
nism for the progression of epithelial cancers.8,9 Molecular
changes in gene expression during EMT have been reported
in thyroid carcinoma progression.10,39,40 In the present
study, we found that the PTC cell lines TPC-1 and BCPAP
undergo EMT under the inﬂuence of TGF-b1, with
decreased expression of E-cadherin and increased expres-
sion of Snail, Slug, and Twist in a time-dependent manner.
Although in a recent study Yasui et al41 did not detect
E-cadherin in the TPC-1 cell line, we found low levels of
E-cadherin in the cell membrane, with higher levels in the
cytoplasm and in the nucleus of these cells, which is sup-
ported by our mRNA data. There was very little cell2349
Figure 6 TGF-b1 induces PRRX1 expression. A:
RT-qPCR analysis of TGF-b1etreated (black bars)
and untreated (gray bars) TPC-1 cells revealed
signiﬁcantly increased PRRX1 expression after TGF-
b1 treatment at days 7, 14, 21, and 30. B:
Immunoblotting and densitometry were performed
for PRRX1 in 28-day TGF-b1etreated and control
cells, as well as RAW cells used as a positive con-
trol, normalized to b-actin. C: PRRX1 immuno-
staining of control and TGF-b1etreated TPC-1 cells
revealed a marked increase in PRRX1 protein
expression on day 14. DAPI was used as a nuclear
counterstain. D and E: RT-qPCR and Western blot
analyses of TPC-1 and BCPAP xenografted tumors
revealed signiﬁcant up-regulation of PRRX1 in TGF-
b1etreated cells, compared with the control me-
diumetreated cells. Data are expressed as
means  SEM for four (A) or two (D and E)
experiments. *P < 0.05, **P < 0.01, and
***P < 0.001. Scale bar Z 50 mm.
Hardin et almembraneeassociated E-cadherin in the TPC-1 and BCPAP
cell lines, compared with NT control tissues or control tis-
sues of primary PTCs, suggesting that these two cell lines
have aberrant expression of E-cadherin.
We observed an increase in CSCs after TGF-b1 treatment
in the PTC cell lines, as evidenced by i) more rapid growth
of tumors by tumor-initiating cells, ii) expression of higher
levels of ALDEFLUOR-positive cells in the xenografted
tumors, iii) up-regulation of the stem cell markers SOX2
and OCT4, and iv) formation of more thyrospheres after
induction of EMT by TGF-b1. In their studies of trans-
formed human mammary epithelial cells, Mani et al8 found
that the mammary cells undergoing EMT had properties of
stem cells, and stem-like cells from mammary carcinomas
expressed EMT markers. Todaro et al5 found that, in pri-
mary thyroid cancers, ALDEFLUOR-high cells were the
cells with CSC properties. However, in a recent study with
thyroid carcinoma cell lines Yasui et al41 demonstrated that2350Snail can induce EMT and cancer stem cell-like properties
in aldehyde dehydrogenaseenegative ACT-1 thyroid cancer
cells. Most studies of EMT in thyroid cancers have analyzed
ATCs.41,42 Our present analysis of two PTC cell lines in-
dicates a role of EMT and CSCs in PTC progression.
PRRX1 is a newly identiﬁed EMT inducer; like many
EMT molecules, it has variable functionality, from devel-
opment to adult stem cell maintenance to EMT and metas-
tasis. In the present study, PRRX1 increased during TGF-b1
induction of EMT in the PTC cell lines in vitro, as well as in
xenografted tumors, indicating that the increase in PRRX1
is relatively stable. In addition, we observed a parallel up-
regulation of PRRX1 and stem cell-like properties. Ocaña
et al20 reported a crucial difference between PRRX1 and
other EMT transcription factors: PRRX1-induced EMT did
not correspond with the induction of stem cell-like proper-
ties during Snail-, Twist-, or Zeb-mediated EMT in mam-
mary cancer cells, and it was PRRX1 loss rather than gainajp.amjpathol.org - The American Journal of Pathology
Table 2 IHC Expression of PRRX1 in Thyroid Tissues
Diagnosis n Positive % Positive
Normal thyroid (NT) 10 2 20*
Nodular goiter (NG) 10 0 0
Follicular adenoma (FA) 32 1 3
Follicular carcinoma (FC) 28 1 4
Papillary thyroid carcinoma (PTC) 57 0 0
Poorly differentiated carcinoma (PDC) 21 0 0
Anaplastic thyroid carcinoma (ATC) 35 20 57.7y
TMAs were constructed and used for IHC staining with PRRX1 antibody.
Staining and quantitation of TMAs were performed as described under
Materials and Methods.
*P < 0.01 for NT versus ATC.
yP < 0.001 for ATC versus NG, FA, FC, PTC, and PDC.
PRRX1 and miR-146b-5p in Thyroid Cancerthat was associated with acquisition of stemness-related
capabilities. Our ﬁndings are in general accord with the
observation of Ocaña et al20 of TGF-b1eregulated expres-
sion of PRRX1; however, in our studies of PRRX1
expression in thyroid cancers we found that it is the higher
grade cancers, such as ATCs, that have the highest per-
centage of cases expressing PRRX1. Our ﬁndings in thyroid
cancer are similar to those of recent studies in colorectal
carcinoma22 and in pancreatic adenocarcinoma21 showing
that EMT and a cancer stem cell-like phenotype are asso-
ciated with increased expression of PRRX1. The distinct
differences across these studies may be related to cell type,
stage of tumor development, or metastatic stage, such as
dormant cells versus colonization of the new tumor cells.43
Further studies are needed to elucidate the various pathways
regulating PRRX1 expression during tumor development
and metastasis in thyroid and other tumors.
The IHC analysis of PRRX1 expression in the TMAs
showed that mainly ATCs expressed this EMT marker.Figure 7 PRRX1 is associated with higher grade thyroid cancers. In
PRRX1 immunostaining of TMA with PTC, hobnail variant of PTC, FC, and
ATC, nuclear staining (brown) indicates positive staining for PRRX1
expression. All PTCs (nZ 57) on the TMA were negative, except 2 out of 5
hobnail variants of PTCs were positive. One out of 28 FC was positive,
whereas 20 out of 36 ATCs were positive for PRRX1. Insets: low-power
image of the corresponding tissue core. Scale bar Z 75 mm.
The American Journal of Pathology - ajp.amjpathol.orgInterestingly, a few NTs (as well as one FA and one
follicular carcinoma) also expressed PRRX1 in the TMA
analysis. Studies in the anterior pituitary have shown
PRRX1 expression in normal pituitary cells.19 In the present
study, we also observed PRRX1 expression in ﬁbroblast and
endothelial cells in the thyroid in the present study. How-
ever, high-grade thyroid carcinomas expressed the highest
level of this EMT marker. All of the conventional PTCs on
the TMAs were negative for PRRX1, as were the corre-
sponding metastases in seven cases. However, two of theFigure 8 TGF-b1 transiently up-regulates miR-146b-5p. A: RT-qPCR
analysis of miR-146b-5p expression from TGF-b1etreated and untreated
TPC-1 cells revealed a signiﬁcant transient up-regulation on day 14 of TGF-
b1 treatment, with subsequent return toward basal levels by day 21. B:
Treated and untreated TPC-1 cells at day 14 were transfected with a
scrambled negative control siRNA or a siRNA speciﬁc for miR-146b-5p and
incubated for 3 days. At the end of the transfection incubation period, MTT
assay indicated that down-regulation of miR-146b-5p signiﬁcantly
increased proliferation in both control and treated cells. C: Invasive
properties of the transfected cells were assessed using a basement mem-
brane extract assay. The invasiveness of TGF-b1etreated cells was unaf-
fected by either the scrambled or the miR-146b-5p siRNA; however, a
signiﬁcant increase in the invasiveness of the control mediumetreated
cells occurred when miR-146b-5p was down-regulated. Data are expressed
as means  SEM for eight (A) or three (B and C) experiments. *P < 0.05;
**P < 0.01. OD, optical density.
2351
Hardin et alPTCs with hobnail features were positive for PRRX1
(Figure 7). Our previous studies have shown that the hobnail
variant of PTC is very aggressive and is associated with
metastatic disease and a high rate of mortality.44,45 One of
the two patients with hobnail variants of PTC positive for
PRRX1 died of metastatic PTC. In the present study, in 6/35
cases of ATC there was PTC associated with ATC, which
supports earlier observations that ATC may sometimes arise
by dedifferentiation from well-differentiated thyroid
carcinomas.46e49 The higher rate of positivity of the ATCs
for PRRX1 may be associated with this dedifferentiation
and progression from PTCs and FCs to ATCs. An alterna-
tive hypothesis is that some ATCs arise from cancer stem
cells that give rise directly to ATCs, as suggested by
Takano.50 However, based on the available evidence from
morphological studies and from analysis of the CSC pop-
ulation in ATCs,5 both of these possible mechanisms may
be important in the development of ATCs.
Conventional PTCs and their corresponding metastases to
lymph nodes were negative for PRRX1; however, the one
ATC and the matching metastases to lymph nodes were
positive for PRRX1. Thus, interestingly, there was no
change in PRRX1 expression in lymph node metastases in
this small set of carcinomas. By contrast, Ocaña et al20
suggested a decrease in PRRX1 from the highest levels,
observed in primary tumors during EMT, to lower levels in
metastatic colonization in their metastatic models.
The differences between our observations in primary
PTCs and the two PTC cell lines may be related to the long
period of time that the cell lines have been in culture, with
changes in the regulation of gene expression during this
period. However, our observation that TGF-b1 stimulates
up-regulation of PRRX1 (as well as other EMT markers,
such as Snail and Slug) indicates that this is an excellent
system for study of the mechanism of PRRX1 regulation in
thyroid carcinomas. Further studies will be needed with
primary and early and late metastatic thyroid carcinomas to
determine the fate of PRRX1 during metastasis and to
determine whether PRRX1 expression changes during EMT
and during mesenchymal-to-epithelial transition in the pro-
cess of colonization in thyroid carcinomas.
In studies using primary PTCs, Swierniak et al51 recently
reported that almost all miRNAs exhibited isoforms of var-
iable length and potentially distinct functions in thyroid
tumorigenesis and that miR-146b-5p was the most highly
deregulated miRNA. Analysis of miR-146b in primary PTCs
has shown that this miRNA is highly expressed in more
aggressive carcinomas.52 In the present study, miR-146b-5p
expression increased 10- to 20-fold transiently during TGF-
b1einduced EMT in the PTC cell lines at approximately day
14 of TGF-b1 treatment. The transient increase in miR-146b-
5p observed in our PTC cell lines suggests that there might be
an initial increase in this miRNA as an attempt to inhibit the
EMT program. Both our present ﬁndings, that cell prolifer-
ation and invasion increased when the expression of miR-
146b-5p was inhibited in the siRNA experiments, and the2352ﬁndings of Geraldo et al,24 that TGF-b1 had an inhibitory
effect of miR-146b-5p translocation of SMAD4 to the cell
nucleus, support this hypothesis. Furthermore, we observed a
signiﬁcant down-regulation of miR-146b-5p expression in
the more aggressive, highly proliferative TGF-b1etreated
xenograft tumors (Supplemental Figure S5A). Nonetheless,
other factors regulating changes in miR-146b-5p will have to
be elucidated in future experiments. Additionally, it has been
shown that miR-146 inhibits EGFR and CXCR4 expression,
which have a positive effect on tumor metastasis in breast
carcinoma.28 EGFR and CXCR4 expression are also asso-
ciated with thyroid cancer progression, with up-regulation of
EGFR in undifferentiated thyroid cancers.53 In our studies of
EGFR expression in the xenografted thyroid carcinomas
derived from TPC-1, there was a signiﬁcant increase in the
expression of EGFR and c-MET in the more rapidly growing
TGF-b1etreated tumors (Supplemental Figure S5B), which
supports their role in thyroid cancer progression.
In summary, the PTC cell lines TPC-1 and BCPAP undergo
EMT under the inﬂuence of TGF-b1 in vitro, which leads to
increased tumor growth in xenografts and an increase in CSC
features in vitro and in vivo. After 10 weeks of growth in vivo,
the TGF-b1etreated tumors expressed higher levels of EMT
biomarkers, compared with control tumors. Expression of the
paired-related homeobox 1 transcription factor PRRX1 was
increased in thyroid PTC cell lines by TGF-b1 treatment and
was also associated with more aggressive thyroid cancers.
Finally, miR-146-5p has an important role in regulating PTC
cell proliferation and invasion, but the regulation of these
changes remains to be elucidated.
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